
State Street SPDR S&P Biotech ETF
XBINYSEARCAState StreetEquity
As of Nov 16, 2026 close
- Assets (AUM)
- $10.19B
- Expense ratio
- 0.35%
- Dividend yield
- 0.37%
- Holdings
- 166
- 52-week range
- $113.06$169.89
- Volume (live)
- -
- Avg. volume (3M)
- 9.68M
XBI ETF Holdings: State Street SPDR S&P Biotech ETF
The largest positions with their portfolio weights, plus sector breakdown and geographic exposure for this Equity ETF. Analyze fund diversification and concentration.
Portfolio Allocations
Distribution breakdown by sector, asset type, and geographic region. Understand the fund's diversification strategy across markets and asset classes.
Loading chart...
Top 52 of 166 XBI Holdings by Portfolio Weight
Holdings data last updated Oct 4, 2026. Ticker, name, asset type and portfolio weight for each position. Fund disclosures available to us list the largest 52 positions.
| # | Symbol | Name | Type | Weight |
|---|---|---|---|---|
| 1 | ![]() | Moderna, Inc | Stock | 2.81% |
| 2 | ![]() | Twist Bioscience Corporation | Stock | 2.20% |
| 3 | ![]() | Natera, Inc. | Stock | 1.82% |
| 4 | ![]() | Iovance Biotherapeutics, Inc. | Stock | 1.59% |
| 5 | ![]() | United Therapeutics Corporation | Stock | 1.57% |
| 6 | ![]() | Spyre Therapeutics, Inc. | Stock | 1.57% |
| 7 | ![]() | AbbVie Inc. | Stock | 1.54% |
| 8 | ![]() | Biogen Inc. | Stock | 1.53% |
| 9 | ![]() | Amgen Inc. | Stock | 1.51% |
| 10 | ![]() | Apogee Therapeutics, Inc. Common Stock | Stock | 1.50% |
| 11 | ![]() | Halozyme Therapeutics, Inc. | Stock | 1.50% |
| 12 | ![]() | CRISPR Therapeutics AG | Stock | 1.49% |
| 13 | ![]() | Exelixis, Inc. | Stock | 1.47% |
| 14 | ![]() | Revolution Medicines, Inc. | Stock | 1.46% |
| 15 | ![]() | Gilead Sciences, Inc. | Stock | 1.46% |
| 16 | ![]() | TG Therapeutics, Inc. | Stock | 1.46% |
| 17 | ![]() | Vertex Pharmaceuticals Incorporated | Stock | 1.42% |
| 18 | ![]() | Protagonist Therapeutics, Inc. | Stock | 1.41% |
| 19 | ![]() | Kymera Therapeutics, Inc | Stock | 1.40% |
| 20 | ![]() | GRAIL, Inc. | Stock | 1.39% |
| 21 | ![]() | PTC Therapeutics, Inc. | Stock | 1.38% |
| 22 | ![]() | Krystal Biotech, Inc. | Stock | 1.36% |
| 23 | ![]() | Neurocrine Biosciences, Inc. | Stock | 1.35% |
| 24 | ![]() | Alkermes plc | Stock | 1.35% |
| 25 | ![]() | Oruka Therapeutics, Inc. | Stock | 1.35% |
| 26 | ![]() | Madrigal Pharmaceuticals, Inc. | Stock | 1.34% |
| 27 | ![]() | Incyte Corporation | Stock | 1.34% |
| 28 | ![]() | Praxis Precision Medicines, Inc | Stock | 1.34% |
| 29 | ![]() | Travere Therapeutics Inc | Stock | 1.30% |
| 30 | ![]() | Dianthus Therapeutics Inc. | Stock | 1.27% |
| 31 | ![]() | CG Oncology, Inc. Common stock | Stock | 1.26% |
| 32 | ![]() | Erasca Inc | Stock | 1.23% |
| 33 | ![]() | Vaxcyte, Inc | Stock | 1.23% |
| 34 | ![]() | Regeneron Pharmaceuticals, Inc | Stock | 1.22% |
| 35 | ![]() | Insmed Incorporated | Stock | 1.22% |
| 36 | ![]() | Scholar Rock Holding Corp | Stock | 1.18% |
| 37 | ![]() | Rhythm Pharmaceuticals, Inc | Stock | 1.14% |
| 38 | ![]() | Roivant Sciences Ltd | Stock | 1.12% |
| 39 | ![]() | Viking Therapeutics Inc | Stock | 1.09% |
| 40 | ![]() | uniQure N.V | Stock | 1.08% |
| 41 | ![]() | Arrowhead Pharmaceuticals, Inc | Stock | 1.07% |
| 42 | ![]() | Relay Therapeutics, Inc | Stock | 1.07% |
| 43 | ![]() | BioMarin Pharmaceutical Inc | Stock | 1.07% |
| 44 | ![]() | Sellas Life Sciences Group Inc | Stock | 1.07% |
| 45 | ![]() | ACADIA Pharmaceuticals Inc | Stock | 1.06% |
| 46 | ![]() | BridgeBio Pharma, Inc | Stock | 1.04% |
| 47 | ![]() | Dyne Therapeutics Inc | Stock | 0.98% |
| 48 | ![]() | Cytokinetics, Incorporated | Stock | 0.97% |
| 49 | ![]() | Immunovant Inc | Stock | 0.97% |
| 50 | ![]() | Mirum Pharmaceuticals Inc | Stock | 0.96% |
| 51 | ![]() | Summit Therapeutics PLC | Stock | 0.94% |
| 52 | ![]() | Celcuity LLC | Stock | 0.93% |
Source: Fund holdings disclosures. Last updated Oct 4, 2026. Data sources and methodology
Frequently Asked Questions About State Street SPDR S&P Biotech ETF Holdings
What are the top holdings in XBI?
In holdings data last updated Oct 4, 2026, XBI's largest holdings are Moderna, Inc (MRNA) at 2.81%, Twist Bioscience Corporation (TWST) at 2.20%, Natera, Inc. (NTRA) at 1.82%, Iovance Biotherapeutics, Inc. (IOVA) at 1.59% and United Therapeutics Corporation (UTHR) at 1.57%. Together these 5 positions make up 10.0% of the fund. XBI holds 166 securities in all; the holdings data lists the top 52 by weight.
How concentrated is XBI's portfolio?
In holdings data last updated Oct 4, 2026, the 10 largest of XBI's 166 positions make up 17.6% of assets. The largest single position is Moderna, Inc (MRNA) at 2.81%. The top 52 listed positions add up to 69.4%, so the remaining 114 holdings share 30.6%. Its largest sector, Healthcare, is 99.3% of the portfolio.
What is XBI's sector allocation?
In holdings data last updated Oct 4, 2026, XBI's largest sector weights are Healthcare (99.3%) and Financials (0.7%), together 100.0% of the portfolio. It has exposure to 2 sectors in total.
What countries does XBI invest in?
In holdings data last updated Oct 4, 2026, 96.6% of XBI's portfolio is invested in the United States, followed by the United Kingdom (1.4%), Switzerland (1.1%) and Netherlands (0.7%). XBI has exposure to 5 countries in total. By asset type the fund is 100.0% stocks.



















































